Business context and reporting period
The supplied filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2022; this differs from the “Chronoscale Holdings Corp” company name in the request metadata. Ekso designs and markets exoskeletons for medical rehabilitation (EksoHealth) and industrial use (EksoWorks). Unless otherwise noted, financial figures below are in millions of dollars.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $3.329 | $3.049 | $9.361 | $7.170 |
| Gross profit / margin | $1.686 / 51% | $1.807 / 59% | $4.536 / 48% | $4.334 / 60% |
| Operating expenses | $5.340 | $4.596 | $15.656 | $13.610 |
| Operating loss | $(3.654) | $(2.789) | $(11.120) | $(9.276) |
| Net loss | $(4.304) | $(1.958) | $(11.902) | $(6.901) |
| Operating cash used | Not stated for quarter | Not stated for quarter | $(11.044) | $(8.081) |
- Q3 revenue grew 9%; nine-month revenue grew 31%. EksoHealth drove growth, while Q3 EksoWorks revenue fell year over year.
- Gross margin fell amid higher service labor, materials, shipping and freight costs, supply-related inventory cost increases, and a 12% year-over-year decrease in aggregate EksoNR average selling price in Q3.
- Cash was $29.180 at September 30, 2022, versus $40.406 at December 31, 2021. Working capital was $28.9, down from $40.9. Approximately $2.0 was required to remain in cash under the loan covenant; the company estimated unrestricted cash of $27.2.
- Total assets were $39.311; total liabilities were $10.697; stockholders’ equity was $28.614. The $2.0 Pacific Western Bank term loan matures in August 2023. The company was in compliance with its liquidity and other loan covenants.
- Nine-month investing cash outflow was $0.141; financing provided no cash in 2022, compared with $38.712 in 2021, primarily from equity issuance and warrant exercises. Cash declined by $11.226 over the first nine months of 2022.
Material changes and unusual items
- Nine-month research and development expense rose 48% to $2.855; general and administrative expense rose 18% to $7.589, including CEO-related stock compensation and severance, business development costs, and relocation expenses.
- Unrealized foreign-exchange losses increased to $1.704 for nine months from $0.640 a year earlier, primarily from remeasurement of intercompany balances. The company reported a $1.011 warrant revaluation gain, versus $2.011 in 2021; these noncash valuation gains partly offset operating losses.
- The prior-year comparison included a $1.099 gain on forgiveness of a PPP loan; there was no equivalent 2022 gain. Nine-month 2022 revenue also included $0.280 of previously deferred royalty revenue from an expired agreement.
- Ekso ceased commercialization of the EksoZeroG support arm and related products at the end of Q2 2022, and does not expect that product line to contribute materially to future EksoWorks revenue.
- The company booked 33 EksoNR units in Q3. It relocated its headquarters and manufacturing facility to San Rafael, California, in August 2022.
Outlook, risks and contingencies
Management stated that unrestricted cash was sufficient to fund operations beyond one year from issuance of the financial statements. This is management’s assessment, not a financial-performance guarantee; the company has an accumulated deficit of $220.769 and continued operating cash outflows. No quantified revenue or earnings guidance was provided.
Management cited supply shortages, longer lead times and higher component and manufacturing costs; inflation and potential price competition; long and variable sales cycles; foreign-currency exposure; and continuing uncertainty related to COVID-19 and geopolitical conditions. The company had $3.203 of purchase obligations expected to be paid within one year and $1.579 of operating lease commitments. Management believed ordinary-course legal matters would not materially affect the financial statements, while noting litigation outcomes cannot be predicted. No material changes to previously disclosed risk factors were identified.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not the company named in the request metadata.
- Assess cash burn against the $27.2 million estimated unrestricted cash balance, the $2.0 million loan maturity in August 2023, and management’s liquidity outlook.
- Track whether revenue growth converts into improved gross margins and lower operating losses, particularly as supply, service and freight costs evolve.
- Evaluate customer concentration: two customers represented 20% and 14% of Q3 revenue; two customers accounted for 13% and 12% of accounts receivable.
- Monitor execution after the EksoZeroG exit and facility move, as well as foreign-exchange exposure and the impact of warrant remeasurement on reported results.